SG Americas Securities LLC Lowers Position in Ocular Therapeutix, Inc. $OCUL

SG Americas Securities LLC trimmed its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 71.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 26,987 shares of the biopharmaceutical company’s stock after selling 66,675 shares during the quarter. SG Americas Securities LLC’s holdings in Ocular Therapeutix were worth $229,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in OCUL. Steward Partners Investment Advisory LLC raised its stake in shares of Ocular Therapeutix by 124.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 2,242 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,242 shares in the last quarter. Rockefeller Capital Management L.P. purchased a new stake in shares of Ocular Therapeutix in the fourth quarter valued at approximately $31,000. Hilton Head Capital Partners LLC purchased a new stake in shares of Ocular Therapeutix in the fourth quarter valued at approximately $42,000. Atlas Capital Advisors Inc. acquired a new position in Ocular Therapeutix during the fourth quarter worth $61,000. Finally, KBC Group NV acquired a new position in Ocular Therapeutix during the fourth quarter worth $78,000. 59.21% of the stock is owned by hedge funds and other institutional investors.

Ocular Therapeutix Price Performance

Shares of OCUL stock traded down $0.34 during mid-day trading on Friday, reaching $10.20. The stock had a trading volume of 1,875,627 shares, compared to its average volume of 3,074,943. Ocular Therapeutix, Inc. has a 12-month low of $6.23 and a 12-month high of $16.44. The company has a market cap of $2.23 billion, a P/E ratio of -6.99 and a beta of 0.88. The business has a 50-day simple moving average of $9.19 and a 200 day simple moving average of $9.53. The company has a current ratio of 14.81, a quick ratio of 14.73 and a debt-to-equity ratio of 0.12.

Insider Buying and Selling

In other Ocular Therapeutix news, insider Pravin Dugel sold 21,156 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $8.20, for a total transaction of $173,479.20. Following the completion of the transaction, the insider directly owned 2,597,170 shares in the company, valued at approximately $21,296,794. This trade represents a 0.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 28,999 shares of company stock valued at $237,792. 3.10% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have commented on OCUL. Chardan Capital raised their target price on Ocular Therapeutix from $21.00 to $23.00 and gave the company a “buy” rating in a report on Thursday, June 25th. Robert W. Baird increased their price target on shares of Ocular Therapeutix from $24.00 to $30.00 and gave the company an “outperform” rating in a report on Thursday, June 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ocular Therapeutix in a research note on Tuesday, April 21st. Needham & Company LLC reissued a “buy” rating and set a $18.00 price objective on shares of Ocular Therapeutix in a report on Tuesday, May 5th. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $30.00 price objective on shares of Ocular Therapeutix in a report on Wednesday, May 6th. Twelve research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $25.11.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.